中轴型脊柱关节炎是一类免疫介导的慢性炎症性疾病，酪氨酸激酶（JAK）抑制剂因其独特的口服给药途径和广谱的细胞因子抑制作用为中轴型脊柱关节炎的治疗带来了新的方向。JAK抑制剂托法替布、乌帕替尼、非戈替尼和艾玛昔替尼可显著改善中轴型脊柱关节炎患者的疾病活动度，具有更好的安全性。总结了酪氨酸激酶抑制剂治疗中轴型脊柱关节炎的研究进展，为传统治疗应答不足的中轴型脊柱关节炎患者提供重要的口服靶向治疗选择。

Axial spondyloarthritis is a type of immune-mediated chronic inflammatory disease, and Janus kinase (JAK) inhibitors have brought new directions for the treatment of axial spondyloarthritis due to their unique oral administration route and broad-spectrum cytokine inhibition. JAK inhibitors, such as tofacitinib, upadacitinib, filgotinib, and ivarmacitinib can significantly improve disease activity in patients with axial spondyloarthritis and have better safety. This article summarizes the research progress of JAK inhibitors in treatment of axial spondyloarthritis, providing an important oral targeted therapy option for patients with axial spondyloarthritis who have insufficient response to traditional treatments.

R982

中国医药教育协会科研课题（HJ-RD-2024-24）；上海市长宁区卫生健康委员会资助课题（长卫健复[2022]20号）